Pure Global
NCT03942042

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Eli Lilly and Company·Phase 4·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Generalized Pustular Psoriasis,Erythrodermic Psoriasis
Drug/Device/Intervention
Ixekizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Nagoya,Sendai-shi,Hirakata,Itabashi-ku,Minato-Ku,Shinjuku-ku,Osaka, Japan
Timeline & enrollment
Phase
Phase 4
Start date
Jul 05, 2019
End date
Jul 22, 2020
Enrollment
12 participants
Primary outcome

Maintenance Dosing Period: Number of Participants Who Improved Global Improvement Score (GIS) at Least 1 Point From Week 12 Through Week 20 and With ≤2 of GIS

Summary

The reason for this study is to see if the study drug ixekizumab is safe and effective in
 participants with generalized pustular psoriasis and erythrodermic psoriasis.

ICD-10 classifications
Generalized pustular psoriasisPsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT03942042
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT03942042 through Pure Global AI's free database. This Phase 4 trial is sponsored by Eli Lilly and Company and is currently Completed. The study focuses on Generalized Pustular Psoriasis,Erythrodermic Psoriasis. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.